Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the <scp>EMPA‐REG OUTCOME</scp> trialChristoph Wanner, Audrey Koitka‐Weber, Michaela Mattheus et al.|Diabetes Obesity and Metabolism|2020Cited by 36
Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEYGreco Mark Malijan, William G. Herrington, Rebecca J. Sardell et al.|American Journal of Kidney Diseases|2025Cited by 8